Oncology
🇪🇺 EMA Page 8EMA news and analysis for pharmaceutical BD, investment, and market access · 10 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 85–94 of 94 articles
EU HTA Radioligand Therapy Assessment: Price, Access & Challenges
Adagene's Muzastotug Shows 66.7% Response Rate in Triple Combination Therapy for Hepatocellular Carcinoma at AACR 2026
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
Boehringer Ingelheim and Zai Lab Launch Phase Ib/II Trial for DLL3-Targeting Combination Therapy in Small Cell Lung Cancer
Medicenna's Bizaxofusp Shows Promise in Brain Cancer Trials Ahead of 2026 Investor Conference
GlycoNex GNX1021 Gets PMDA Approval for First-in-Human Phase 1 Trial in Gastrointestinal Cancers
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
EMA Backs Amgen's Tarlatamab as First-in-Class BiTE Therapy for Advanced Small Cell Lung Cancer
EMA Recommends First Bispecific T-Cell Engager for Relapsed Small Cell Lung Cancer
CHMP Positive Opinion CAR-T Therapy: What You Need to Know